The original version of this Letter contains an error in Figure 5, concerning an experiment performed at University of Bologna, which shows the effect of the tested compounds on microglial activation. In the incorrect published Figure 5, the GAPDH band (housekeeping protein used as loading control) from a preliminary experiment for compound 1 was accidentally shown, and the correct image is used below. Furthermore, since we used the same LPS-treated control microglial cells for compounds 11 and 12, being that they were tested in the same experiment and plate, the right two panels have been modified for clarity. This is the correct Figure 5:.(Figure Presented).

Correction: Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent to Combat Alzheimer's Disease (ACS Medicinal Chemistry Letters (2019) 10: 4 (469−474) DOI: 10.1021/acsmedchemlett.8b00507) / De Simone A.; La Pietra V.; Betari N.; Petragnani N.; Conte M.; Daniele S.; Pietrobono D.; Martini C.; Petralla S.; Casadei R.; Davani L.; Frabetti F.; Russomanno P.; Novellino E.; Montanari S.; Tumiatti V.; Ballerini P.; Sarno F.; Nebbioso A.; Altucci L.; Monti B.; Andrisano V.; Milelli A.. - In: ACS MEDICINAL CHEMISTRY LETTERS. - ISSN 1948-5875. - STAMPA. - 10:9(2019), pp. 1357-1357. [10.1021/acsmedchemlett.9b00316]

Correction: Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent to Combat Alzheimer's Disease (ACS Medicinal Chemistry Letters (2019) 10: 4 (469−474) DOI: 10.1021/acsmedchemlett.8b00507)

De Simone A.;Betari N.;Daniele S.;Petralla S.;Casadei R.;Davani L.;Frabetti F.;Montanari S.;Tumiatti V.;Monti B.;Andrisano V.;Milelli A.
2019

Abstract

The original version of this Letter contains an error in Figure 5, concerning an experiment performed at University of Bologna, which shows the effect of the tested compounds on microglial activation. In the incorrect published Figure 5, the GAPDH band (housekeeping protein used as loading control) from a preliminary experiment for compound 1 was accidentally shown, and the correct image is used below. Furthermore, since we used the same LPS-treated control microglial cells for compounds 11 and 12, being that they were tested in the same experiment and plate, the right two panels have been modified for clarity. This is the correct Figure 5:.(Figure Presented).
2019
Correction: Discovery of the First-in-Class GSK-3β/HDAC Dual Inhibitor as Disease-Modifying Agent to Combat Alzheimer's Disease (ACS Medicinal Chemistry Letters (2019) 10: 4 (469−474) DOI: 10.1021/acsmedchemlett.8b00507) / De Simone A.; La Pietra V.; Betari N.; Petragnani N.; Conte M.; Daniele S.; Pietrobono D.; Martini C.; Petralla S.; Casadei R.; Davani L.; Frabetti F.; Russomanno P.; Novellino E.; Montanari S.; Tumiatti V.; Ballerini P.; Sarno F.; Nebbioso A.; Altucci L.; Monti B.; Andrisano V.; Milelli A.. - In: ACS MEDICINAL CHEMISTRY LETTERS. - ISSN 1948-5875. - STAMPA. - 10:9(2019), pp. 1357-1357. [10.1021/acsmedchemlett.9b00316]
De Simone A.; La Pietra V.; Betari N.; Petragnani N.; Conte M.; Daniele S.; Pietrobono D.; Martini C.; Petralla S.; Casadei R.; Davani L.; Frabetti F.; Russomanno P.; Novellino E.; Montanari S.; Tumiatti V.; Ballerini P.; Sarno F.; Nebbioso A.; Altucci L.; Monti B.; Andrisano V.; Milelli A.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/779672
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact